Therapeutic vulnerabilities associated with PTEN missense mutations

与 PTEN 错义突变相关的治疗漏洞

基本信息

批准号：
10056208
负责人：
Alain Charest
金额：
$ 20.45万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-12-01 至 2021-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10056208
关键词：
Alleles Animals Area Astrocytes Attenuated Biological Models Cancer Patient Categories Cells Clinical Management Clinical Trials Clustered Regularly Interspaced Short Palindromic Repeats Complement Development Engineering Epidermal Growth Factor Receptor Event Genes Genetic Genetic Engineering Genetically Engineered Mouse Genomics Genotype Glioblastoma Gliomagenesis Goals Human In Vitro Inherited Introns Knock-in Lead Ligands Lipids MAP Kinase Gene MEK inhibition MEKs Malignant - descriptor Malignant Neoplasms Malignant neoplasm of brain Missense Mutation Modeling Molecular Mouse Strains Mus Mutant Strains Mice Mutation Outcome PTEN gene Pathogenesis Pathway interactions Phosphoric Monoester Hydrolases Point Mutation Pre-Clinical Model Protein Isoforms Proto-Oncogene Proteins c-akt Research Research Project Grants Resistance Role Series Signal Pathway Signal Transduction Stratification System Therapeutic Therapeutic Intervention Treatment Protocols Tumor Suppression Tumor-Derived Variant Work cancer therapy cell transformation conditional mutant embryonic stem cell epidermal growth factor receptor VIII homologous recombination human disease in vivo inhibitor/antagonist insight metaplastic cell transformation mouse model mutant mutational status novel novel therapeutics overexpression pre-clinical preclinical study programs targeted treatment tumor tumorigenesis

项目摘要

Project Summary/Abstract Genetic loss or acquisition of missense mutations within the phosphatase and tensin homolog (PTEN) gene is a frequent event in glioblastoma multiforme (GBM). Loss of PTEN activity leads to a robust activation of PI3K signaling due to its established role as a lipid phosphatase but also to an activation of the MAPK pathway. Missense mutations within PTEN that retain phosphatase catalytic activity are common in GBM and we demonstrate their capacity to drive gliomagenesis in vitro. The molecular mechanisms by which these mutations abrogate PTEN's tumor suppressive function are unknown and represent a crucial area of research in cancer. We hypothesize that phosphatase activity-retaining missense mutations are not synonymous to complete loss of PTEN or phosphatase activity dead missense mutants in their mechanisms of tumor suppression and represent distinct categories of PTEN driven cancers that will respond differently to PI3K- and MEK-centric treatment regimens. On this basis, we propose to 1) develop new PTEN genetically engineered mouse models of missense mutants and utilize these models to optimize targeted therapies against PI3K and MEK, and 2) create isogenic PTEN missense mutant human GBM PDX lines to uncover new PI3K and MEK inhibition strategies. The overall goal of the proposed research is to deliver on an effective translational use of genetically cutting edge models of GBM that accurately recapitulate human disease to direct research toward the development of new treatments.

项目摘要/摘要在磷酸酶和Tensin同源物（PTEN）基因内的遗传丧失或获取错义突变为多形胶质母细胞瘤（GBM）的经常事件。 PTEN活性的丧失导致PI3K的强大激活信号是由于其确定的作用是脂质磷酸酶，也是由于MAPK途径的激活而引起的。在PTEN内保留磷酸酶催化活性的错义突变在GBM中很常见，我们证明了它们在体外驱动神经胶质作用的能力。这些分子机制突变消除了PTEN的肿瘤抑制功能未知，代表了至关重要的研究领域在癌症中。我们假设磷酸酶活性的失误突变不是同义词为了完成PTEN或磷酸酶活性死亡错义突变体的丧失。肿瘤抑制并代表了将有反应的PTEN驱动癌症的不同类别与以PI3K和MEK为中心的治疗方案不同。在此基础上，我们建议1）开发新的 PTEN基因设计的错义突变体的鼠标模型，并利用这些模型来优化针对PI3K和MEK的有针对性疗法，以及2）创建ISEGENIC PTEN失误突变体人GBM PDX 发现新的PI3K和MEK抑制策略的行。拟议研究的总体目标是提供了精确概括的GBM基因前沿模型的有效翻译使用人类疾病直接研究新疗法的发展。